Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06974786 · ClinicalTrials.gov registry record · Phase 2
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
A Phase 2 study of Multiple Myeloma (MM) and Multiple Myeloma, Newly Diagnosed, sponsored by SCRI Development Innovations.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT06974786 is a Phase 2 study of Multiple Myeloma (MM) and Multiple Myeloma, Newly Diagnosed that is actively recruiting participants, run by SCRI Development Innovations. The registered enrollment target is 100 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT06974786, a Phase 2 study of Multiple Myeloma (MM) and Multiple Myeloma, Newly Diagnosed, is actively recruiting participants, sponsored by SCRI Development Innovations.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Elranatamab
- DRUG Daratumumab
- PROCEDURE autologous stem cell transplantation
Study Locations (9)
Wisconsin
- University of Wisconsin Clinical Science Center - Madison
- Medical College of Wisconsin - Milwaukee
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Colorado Blood Cancer Institute - Denver
Iowa
- University of Iowa - Iowa City
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Oncology Hematology Care - Cincinnati
Tennessee
- SCRI Oncology Partners - Nashville
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-08-08 |
| Est. Completion | 2033-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06974786
The ClinicalTrials.gov registry entry for NCT06974786 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma (MM) appearing as the primary indexed condition, and to 4 interventions - of which Lenalidomide is the first listed.
NCT06974786 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Wisconsin, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT06974786 about?
NCT06974786 is a clinical study titled "Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma". This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease ...
What is the current status of trial NCT06974786?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-08-08. Estimated completion is 2033-04.
What conditions does trial NCT06974786 study?
This clinical trial studies the following conditions: Multiple Myeloma (MM), Multiple Myeloma, Newly Diagnosed.
What interventions are being tested in trial NCT06974786?
The interventions under investigation include: Lenalidomide (DRUG), Elranatamab (DRUG), Daratumumab (DRUG), autologous stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT06974786?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06974786 being conducted?
This trial has 9 study locations across Alabama, Colorado, Iowa, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma (MM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.